Withaferin A Rescues Brain Network Dysfunction and Cognitive Deficits in a Mouse Model of Alzheimer's Disease

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, marked by cognitive decline and neural network issues.
• Current research focuses on developing effective anti-AD drugs, including natural compounds.
• Withaferin A (WA), from Withania somnifera, shows potential in reducing amyloid-beta (Aβ) in vitro, but its cognitive effects in AD are unknown.

Purpose of the Study:

• To investigate the neuroprotective effects of Withaferin A (WA) in a mouse model of Alzheimer's disease.
• To evaluate WA's impact on cognitive function, neural network activity, and Aβ pathology.

Main Methods:

• 5xFAD mice received WA (2 mg/kg) intraperitoneally every two days for 14 days.
• Neuroprotection was assessed using behavioral tests (NORT, NLRT, TCST, MWMT), wide-field Ca2+ imaging, immunohistochemistry, and ELISA.

Main Results:

• WA significantly improved short-term and long-term memory in behavioral tests.
• Cortical wide-field Ca2+ imaging showed WA rescued slow-wave impairments by enhancing long-range coherence.
• WA treatment markedly reduced amyloid-beta (Aβ) plaque deposition in cortical and hippocampal regions.

Conclusions:

• Withaferin A (WA) demonstrates significant neuroprotective effects in an Alzheimer's disease mouse model.
• WA improves cognitive function and reduces key AD pathologies, suggesting its therapeutic potential.